Winslow Evans & Crocker INC Position in Edwards Lifesciences Corp (EW) Cut by $45.08 Million

April 17, 2018 - By Duane Lopez

Edwards Lifesciences Corporation (NYSE:EW) Logo

Winslow Evans & Crocker Inc decreased its stake in Edwards Lifesciences Corp (EW) by 0.73% based on its latest 2017Q4 regulatory filing with the SEC. Winslow Evans & Crocker Inc sold 400 shares as the company’s stock rose 22.78% while stock markets declined. The institutional investor held 54,562 shares of the industrial specialties company at the end of 2017Q4, valued at $6.15B, down from 54,962 at the end of the previous reported quarter. Winslow Evans & Crocker Inc who had been investing in Edwards Lifesciences Corp for a number of months, seems to be less bullish one the $29.05B market cap company. The stock decreased 0.09% or $0.12 during the last trading session, reaching $138. About 814,390 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since April 17, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

Winslow Evans & Crocker Inc, which manages about $600.60M and $311.16 billion US Long portfolio, upped its stake in Wisdomtree Tr (DES) by 1,200 shares to 1,800 shares, valued at $52.29 million in 2017Q4, according to the filing. It also increased its holding in Ishares Tr (TIP) by 400 shares in the quarter, for a total of 1,330 shares, and has risen its stake in Marathon Pete Corp (NYSE:MPC).

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on April, 24. They expect $1.10 earnings per share, up 17.02 % or $0.16 from last year’s $0.94 per share. EW’s profit will be $231.57M for 31.36 P/E if the $1.10 EPS becomes a reality. After $0.94 actual earnings per share reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts 17.02 % EPS growth.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

Among 15 analysts covering Edwards Lifesciences (NYSE:EW), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Edwards Lifesciences had 29 analyst reports since October 25, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, December 7 by BMO Capital Markets. The firm earned “Buy” rating on Thursday, February 1 by Cowen & Co. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Friday, February 2 by Guggenheim. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Wednesday, January 17 by BMO Capital Markets. The stock has “Buy” rating by Canaccord Genuity on Thursday, March 22. RBC Capital Markets maintained it with “Buy” rating and $140.0 target in Friday, February 2 report. On Wednesday, November 29 the stock rating was maintained by Canaccord Genuity with “Buy”. Barclays Capital maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Wednesday, October 25. Barclays Capital has “Equal-Weight” rating and $118 target. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Overweight” rating by Morgan Stanley on Friday, February 2. On Thursday, December 7 the stock rating was maintained by Jefferies with “Buy”.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: